Conference Reports for NATAP

Back

International AIDS Conference (IAS) Rio de Janeiro, Brazil July 24-27, 2005     Characterization of Anemia in HIV+ Subjects Treated with ART With and Without Zidovudine in 54 Clinical Trials (09/13/05)   Abacavir/3TC+EFV: two pills once daily(09/13/05)   Antiretrovirals: New and novel use thereof - Reported by Mike Youle, MD, Royal Free Hospital, London, UK (09/09/05)   Hepatocellular carcinoma in 40 HIV/HCV-coinfected versus 50 HCV-monoinfected patients. North American HCC in HIV Study Gro (09/09/05)   Caucasians Had Better HCV Viral Load Reductions Than African-Americans During First 3 Days & During Weeks 1-4 After Starting Peg/RBV (09/09/05)   Hepatitis C infection is not associated with systemic HIV-associated non-Hodgkin's lymphoma: a cohort study (09/09/05)   PI & NNRTI Drug Levels in Coinfected Patients (09/09/05)   Pegasys/RBV Improves Histology in Non-Responders & Cirrhotics (09/09/05)   PegIFN/RBV May Be Less Effective in Acute HCV for HIV+ (09/09/05)   PK of Once Daily Regimen: Fosamprenavir/r, Tenofovir and FTC in Naives (09/09/05)   PK of Once Daily Regimen: Fosamprenavir/r, Tenofovir and FTC in Naives (08/31/05)   HIV+ Patient Survey: 52% Dissatisfied with Quality of Life (08/31/05)   Uridine In Vitro Improves Mitochondrial Effect of Nukes (08/31/05)   Tipranavir & Effect of Using Active HIV Drugs (08/30/05)   Tipranavir: long-term safety/tolerability (08/30/05)   The Pharmacokinetics (PK) of Single-dose and Steady-state Tipranavir/Ritonavir (TPV/r) 500 mg/200 mg in Subjects With Mild or Moderate Hepatic Impairment (08/30/05)   PK of Once Daily Regimen: Fosamprenavir/r, Tenofovir and FTC in Naives (08/30/05)   Abacavir vs d4T: changes in viral load, diabetes, lipids, body changes, cytokines (08/30/05)   6% New Onset Diabetes in D.A.D. Study: Risk factors for new onset diabetes mellitus (DM) in HIV patients (08/30/05)   New NNRTI GW695634: safety & antiviral activity; 7-day monotherapy study (08/17/05)   "Thyroid Dysfunction in Individuals with HIV Infection: the effect of HAART" (08/15/05)   873140 Exhibits Potent Antiviral Activity Against a Broad Panel of HIV-1 Envelopes From Treatment Naive and Experienced Subjects (08/11/05)   The StARS Study: Once Daily Atazanavir, Low-Dose Ritonavir and Saquinavir : 24 Week Efficacy, PK, and Safety Results (08/11/05)   "Evaluation of Hyperpigmentation in HIV-Infected Patients Receiving Emtricitabine (FTC, Emtriva)" (08/11/05)   Switch to Tenofovir: lipoatrophy, Adverse Events Outcomes (08/11/05)   PATIENTS TREATED WITH RITONAVIR-BOOSTED SAQUINAVIR" (08/11/05)   Invirase/r: No PI Resistance in viral failures (08/05/05)   Tenofovir DF (TDF) in Combination with Lamivudine (3TC) and Efavirenz (EFV) in Antiretroviral-Naïve HIV-Infected Patients: a 4-Year Follow-Up (08/05/05)   Tenofovir Resistance Report (08/05/05)   Simplification to Kaletra Monotherapy (08/05/05)   Atazanavir Use in Pregnancy (08/05/05)   Cirrhotic Non-Responders Improve Liver Condition with Pegasys/RBV in APRICOT Study (08/05/05)   Tipranavir & TDM (08/03/05)   Once-Daily vs.Twice-Daily Lopinavir/ritonavir in Antiretroviral-Naïve Patients: 96-Week Results (08/03/05)   New Gas-Powered T20 Injection Device: 48 week study (08/03/05)   Abacavir+3TC: Changes in ALT/AST in Coinfected (08/03/05)   24 vs 48 weeks Pegasys/RBV in HCV Genotype 2/3 Coinfection: does this study answer the question (08/01/05)   Substantial improvement of oral bioavailability of TMC125 using new tablet formulations in healthy volunteers (08/01/05)   TMC114-C213 study Week 24 primary analysis Highly Treatment Experienced Patients (08/01/05)   TMC114/r is well tolerated in 3-class-experienced patients: Week 24 primary safety analysis of POWER 1 (TMC114-C213) (08/01/05)   Effect of food and multiple-dose pharmacokinetics of TMC278 as an oral tablet formulation: healthy volunteers (08/01/05)   GlaxoSmithKline begins Phase III trials with aplaviroc (873140) - an entry inhibitor for HIV treatment (07/29/05)   CCR5 Inhibitor SCH417690: antiviral activity (07/29/05)   Switch to Reyataz: lipids, viral load (07/29/05)   Improvement in Facial & Limb Lipoatrophy at 48 Wks After Switch to Abacavir or Tenofovir (07/28/05)   CCR5 INHIBITOR MARAVIROC (UK-427,857) (07/28/05)   Overview of Phase 1 and 2a Safety and Efficacy Data of Maraviroc (UK-427,857) (07/28/05)   New Kaletra Tablet PK Study (07/28/05)   Tenofovir+FTC+Efavrienz vs Combivir+EFV: 48 Week Final Results Study 934 (07/28/05)   TMC-114/r: 24 week efficacy & safety (07/26/05)   Reverset (d4FC), new NRTI: phase IIb data (07/26/05)   Report 1. International AIDS Conference (IAS) in Rio de Janeiro, July 24-27, 2005 (07/25/05)